Wouter Plattel
dr.
As a hematologist I am always looking for new development that might improve patient care. My main research focus is on patients with Hodgkin lymphoma and multiple myeloma. I am involved in both translational and clinical studies. In cooperation with the Pathology, I am active in the field of biomarkers, such as TARC in Hodgkin lymphoma. For the design, development and execution of clinical trials, I am an active member of both international (EORTC) and national (HOVON) organizations. For example, I am the national PI of the EORTC COBRA trial in Hodgkin lymphoma. Moreover, I am co-PI of the translational research in two international trials. In addition, I am part of the Dutch guideline writing committee for Hodgkin lymphoma. In myeloma, I am investigating innovative treatment options to improve outcome.
A population-based study of transformed marginal zone lymphoma: identifying outcome-related characteristics
Published in: Blood cancer journal
Access to document
10.1038/s41408-023-00903-w
document
Histological transformation of marginal zone lymphoma (tMZL) into diffuse large B-cell lymphoma is associated with poor outcomes. Clinical characteristics associated with transformation risk and outcome after transformation are largely unknown due to scarcity of data. In this population-based study, competing risk analyses were performed to elucidate clinical characteristics associated with developing transformation among 1793 MZL patients using the Netherlands Cancer Registry. Cox regression analyses were performed to elucidate clinical characteristics associated with risk of relapse and mortality after transformation. Transformation occurred in 75 (4%) out of 1793 MZL...
Johanna A A Bult, Francien Huisman, Yujie Zhong, Nick Veltmaat, Joost Kluiver, Sanne H Tonino, Joost S P Vermaat, Martine E D Chamuleau, Arjan Diepstra, Anke van den Berg, Wouter J Plattel, Mirian Brink, Marcel Nijland
A significant proportion of classic Hodgkin lymphoma recurrences represents clonally unrelated second primary lymphoma
Published in: Blood Advances
Access to document
10.1182/bloodadvances.2023010412
Despite high cure rates in classic Hodgkin lymphoma (cHL), relapses are observed. Whether relapsed cHL represents second primary lymphoma or an underlying T-cell lymphoma (TCL) mimicking cHL is under-investigated. To analyze the nature of cHL recurrences, in-depth clonality testing of immunoglobulin (IG) and T-cell receptor (TR) rearrangements was performed in paired cHL diagnosis and recurrences of 60 patients, supported by targeted mutation analysis of lymphoma-associated genes. Clonal IG rearrangements were detected by next-generation sequencing (NGS) in 69/120 (58%) diagnosis and recurrence samples. The clonal relationship could be established...
Diede Ag van Bladel, Wendy B C Stevens, Leonie I Kroeze, Ruben Al de Groen, Fleur A de Groot, Jessica Lm van der Last-Kempkes, Madeleine R Berendsen, Jos Rijntjes, Jeroen A C W Luijks, Irina Bonzheim, Ellen van der Spek, Wouter J Plattel, Johannes Pruijt, Susan Dpwm de Jonge-Peeters, Gerjo A Velders, Chantal Lensen, Esther R van Bladel, Birgit Federmann, Brigiet Hoevenaars, Agata PastorczakJutte van der Werff Ten Bosch, Joost S P Vermaat, Peet Nooijen, Konnie M Hebeda, Falko Fend, Arjan Diepstra, J Han Jm van Krieken, Patricia J T A Groenen, Michiel van den Brand, Blanca Scheijen
Work and education interruption in long-term Hodgkin lymphoma survivors: an analysis among patients from nine EORTC-LYSA trials
Published in: ACTA ONCOLOGICA
Access to document
10.1080/0284186X.2023.2195561
Background: Disease-specific studies on the impact of Hodgkin lymphoma (HL) on education or work interruption and resumption are lacking. Material and methods: In a cross-sectional study conducted among long-term HL survivors enrolled from 1964 to 2004 in nine randomised EORTC-LYSA trials, the interruption and resumption of education/work was investigated. Survivors alive 5–44 years after diagnosis who were studying or working at time of diagnosis were included (n = 1646). Patient and treatment characteristics were obtained from trial records. Education and work outcomes were collected using the Life Situation...
Sidsel J. Juul, Sára Rossetti, Michal Kicinski, Marleen A.E. van der Kaaij, Francesco Giusti, Paul Meijnders, Berthe M.P. Aleman, John M.M. Raemaekers, Hanneke C. Kluin-Nelemans, Michele Spina, Christophe Fermé, Loïc Renaud, Olivier Casasnovas, Aspasia Stamatoullas, Marc André, Fabien Le Bras, Wouter J. Plattel, Michel Henry-Amar, Martin Hutchings, Maja V. Maraldo
The value of thymus and activation related chemokine immunohistochemistry in classic Hodgkin lymphoma diagnostics
Published in: Histopathology
Access to document
10.1111/his.14836
document
Aims: Classic Hodgkin lymphoma (cHL) should be distinguished from its wide variety of histological mimics, including reactive conditions and mature B and T cell neoplasms. Thymus and activation-related chemokine (TARC) is produced in extremely high quantities by the Hodgkin/Reed–Sternberg (HRS) tumour cells and is largely responsible for the attraction of CD4+ T cells into the cHL tumour micro-environment. In the current study we evaluated the diagnostic potential of TARC immunohistochemistry in daily practice in a tertiary referral centre in the Netherlands. Methods and results: A total of 383...
Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP
Published in: Leukemia
Access to document
10.1038/s41375-022-01717-8
document
Risk-stratified treatment strategies have the potential to increase survival and lower toxicity in relapsed/refractory classical Hodgkin lymphoma (R/R cHL) patients. This study investigated the prognostic value of serum (s)TARC, vitamin D and lactate dehydrogenase (LDH), TARC immunohistochemistry and quantitative PET parameters in 65 R/R cHL patients who were treated with brentuximab vedotin (BV) and DHAP followed by autologous stem-cell transplantation (ASCT) within the Transplant BRaVE study (NCT02280993). At a median follow-up of 40 months, the 3-year progression free survival (PFS) was 77% (95% CI: 67–88%) and the overall...
HOVON Lunenburg Lymphoma Phase I/II Consortium (LLPC), Julia Driessen, Marie José Kersten, Lydia Visser, Anke van den Berg, Sanne H. Tonino, Josée M. Zijlstra, Pieternella J. Lugtenburg, Franck Morschhauser, Martin Hutchings, Sandy Amorim, Thomas Gastinne, Marcel Nijland, Gerben J.C. Zwezerijnen, Ronald Boellaard, Henrica C.W. de Vet, Anne I.J. Arens, Roelf Valkema, Roberto D.K. Liu, Esther E.E. DreesDaphne de Jong, Wouter J. Plattel, Arjan Diepstra